vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Core Viewpoint - vTv Therapeutics Inc. is advancing its late-stage biopharmaceutical candidate cadisegliatin, aimed at treating type 1 diabetes, with recent developments including the initiation of a Phase 3 trial and financial results indicating ongoing investment in research and development [2][3][5]. Recent Company Highlights - The first participant has been randomized in the CATT1 Phase 3 trial for cadisegliatin, with topline data expected in the second half of 2026 [6][7]. - The intellectual property portfolio for cadisegliatin has been expanded, with a patent application for crystalline forms allowed, extending the patent term through 2041 [7]. - Michael Tung has been appointed as Chief Financial Officer, bringing over 20 years of experience in financial management and strategic leadership [7]. Second Quarter 2025 Financial Results - As of June 30, 2025, the company's cash position was $25.9 million, down from $36.7 million at the end of 2024 [7]. - Research and Development (R&D) expenses increased to $4.1 million from $3.4 million in the same quarter of 2024, primarily due to higher payroll costs [7]. - General and Administrative (G&A) expenses decreased slightly to $3.6 million from $3.7 million year-over-year [7]. - The net loss attributable to vTv shareholders for the quarter was $6.0 million, or $0.92 per share, compared to a net loss of $5.2 million, or $0.81 per share, in the same period last year [8][12].